Business Context and Reporting Period
This Form 8-K is filed by Actinium Pharmaceuticals, Inc. (ATNM) on May 27, 2026. The report addresses a notice received from NYSE American LLC regarding the Company's non-compliance with continued listing standards due to insufficient stockholders' equity and a history of net losses.
Key Financial Metrics
- Stockholders' Equity: Approximately $2.3 million as of March 31, 2026.
- Profitability: The Company reported net losses in its last five fiscal years ended December 31, 2025.
- Listing Requirement: NYSE American requires listed companies with losses in three of the last four fiscal years to maintain stockholders' equity of at least $4.0 million.
- Revenue, Cash Flow, Debt, and Margins: The filing text does not provide specific values for revenue, operating cash flow, debt levels, or profit margins.
Material Changes and Compliance Status
The primary material change is the receipt of a delisting notice. The Company's stockholders' equity of $2.3 million falls below the $4.0 million threshold required for companies with a history of losses. Consequently, the Company's stock will continue to trade on NYSE American under the symbol "ATNM" but will carry a ".BC" indicator denoting "Below Compliance."
Outlook, Risks, and Management Commentary
- Compliance Plan Deadline: The Company must submit a plan to regain compliance by June 26, 2026.
- Target Compliance Date: The plan must demonstrate actions to meet listing standards by November 27, 2027.
- Risks: There is no assurance that the Company will submit an acceptable plan, regain compliance, or maintain its listing. Failure to submit a plan, have it accepted, or meet the November 2027 deadline will result in delisting proceedings.
- Management Action: The Company intends to submit a plan within the required timeframe. A press release dated May 29, 2026, also provided an update on the ATNM-400 product candidate.
Investor Verification Checklist
- Verify the specific details of the compliance plan to be submitted by June 26, 2026.
- Monitor the ".BC" trading indicator on NYSE American for ATNM stock.
- Review the May 29, 2026 press release for updates on the ATNM-400 product candidate and potential capital raising activities.
- Assess the Company's ability to raise capital or improve equity to meet the $4.0 million threshold by November 27, 2027.